Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antithymocyte globulin rabbit + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Peking University People's Hospital
- Modality
- Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Reduced ATG + mini PTCy is a combination graft-versus-host disease (GVHD) prophylaxis regimen consisting of reduced-dose anti-thymocyte globulin (ATG) and mini-dose post-transplant cyclophosphamide (PTCy). This regimen is primarily investigated for use in haploidentical hematopoietic stem cell transplantation (haplo-HSCT) for patients with hematologic malignancies such as acute leukemia and myelodysplastic syndromes (MDS). ATG is a polyclonal antibody preparation that depletes T-cells in vivo, while cyclophosphamide is an alkylating agent administered post-transplant to selectively eliminate proliferating alloreactive T-cells. The combination aims to synergistically reduce the incidence of both acute and chronic GVHD while potentially improving immune reconstitution and reducing infection-related mortality compared to standard-dose ATG protocols.
- Other names
- Reduced ATG + mini PTCyReduced-dose Anti-thymocyte Globulin Plus Mini-dose Post-transplant Cyclophosphamide
02
Targets
DNA
Beyond the preview
Go deeper on antithymocyte globulin rabbit + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antithymocyte globulin rabbit + cyclophosphamide.